Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J, Kamm CP, Kaufmann M, Stanikić M, Puhan MA, Kesselring J, Zecca C, Gobbi C, Rapold I, Kurmann R, Ammann S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Bossart J, et al. Among authors: kamm cp. Mult Scler Relat Disord. 2022 Apr;60:103706. doi: 10.1016/j.msard.2022.103706. Epub 2022 Feb 21. Mult Scler Relat Disord. 2022. PMID: 35228114 Free article.
Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.
Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, Schwegler G, Schött D, Donati F, Müller M, Goebels N, Müller F, Slotboom J, Tettenborn B, Kappos L, Naegelin Y, Mattle HP. Kamm CP, et al. J Neurol. 2012 Nov;259(11):2401-13. doi: 10.1007/s00415-012-6513-7. Epub 2012 May 9. J Neurol. 2012. PMID: 22569835 Free PMC article. Clinical Trial.
Natalizumab in spinal multiple sclerosis in a daily clinical setting.
Zecca C, Heldner MR, Kamm CP, Riccitelli GC, Disanto G, Caporro M, Cianfoni A, Pravatà E, Gobbi C. Zecca C, et al. Among authors: kamm cp. Expert Opin Biol Ther. 2015 May;15(5):633-40. doi: 10.1517/14712598.2015.1025046. Epub 2015 Apr 3. Expert Opin Biol Ther. 2015. PMID: 25840751
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board. Disanto G, et al. Among authors: kamm cp. PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016. PLoS One. 2016. PMID: 27032105 Free PMC article.
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Disanto G, et al. Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954. Ann Neurol. 2017. PMID: 28512753 Free PMC article.
The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
Barin L, Salmen A, Disanto G, Babačić H, Calabrese P, Chan A, Kamm CP, Kesselring J, Kuhle J, Gobbi C, Pot C, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Barin L, et al. Among authors: kamm cp. Mult Scler Relat Disord. 2018 Oct;25:112-121. doi: 10.1016/j.msard.2018.07.013. Epub 2018 Jul 21. Mult Scler Relat Disord. 2018. PMID: 30059895
90 results